Session 97 - 12th CROI

Home

Session 97 Poster Abstracts
New Antiretroviral Agents: RTIs and Pis
Thursday, 1:30 - 3:30 pm
Hall A

553	A Randomized, Placebo-controlled Trial of Amdoxovir vs Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-infected Subjects Failing Current Therapy (AACTG 5118) Barbara Gripshover*¹, J Santana², H Ribaudo³, J Gerber⁴, C Thomas⁵, E Hogg⁶, B Jarocki⁷, S Hammer⁸, and D Kuritzkes⁹ ¹Univ Hosp of Cleveland, Case Western Reserve Univ, OH, USA; ²Univ of Puerto Rico Sch of Med, San Juan; ³Harvard Sch of Publ Hlth, Boston, MA, USA; ⁴Univ of Colorado Hlth Sci Ctr, Denver, USA; ⁵Univ of Colorado Hlth Sci Ctr, Denver, USA; ⁶ACTG Operations Office, Silver Spring, MD, USA; ⁷Frontier Sci & Tech Res Fndn, Amherst, NY, USA; ⁸Columbia Presbyterian Med Ctr, New York, NY, USA; and ⁹Brigham & Women's Hosp, Harvard Med Sch, Boston, MA, USA
554	Dioxolane Thymine Nucleoside Is Active against a Variety of NRTI-resistant Mutants Chung K Chu*¹, V Yadav¹, K Rapp², Y Chong¹, and R Schinazi² ¹Athens, Georgia, USA and ²Atlanta, GA, USA
555	24 Week Safety, Tolerability, and Efficacy of Capravirine as Add-on Therapy to Nelfinavir and 2 Nucleoside Reverse Transcriptase Inhibitors in Patients Failing a Non-nucleoside Reverse Transcriptase Inhibitor-based Regimen Rick Pesano*¹, S Piraino², P Hawley², J Hammond², R Tressler³, R Ryan², D Nickens², R Ruiz², and 1002 Study Group ¹Pfizer Global Res and Devt, La Jolla, CA, USA; ²Pfizer Global Res and Devt, La Jolla, CA, USA; and ³Pfizer Global Pharma, New York, NY, USA
556	TMC278, a New Potent NNRTI, with an Increased Barrier to Resistance and Good Pharmacokinetic Profile Marie-Pierre de Béthune*¹, K Andries², H Azijn¹, J Guillemont³, J Heeres², J Vingerhoets¹, P Lewi², E Lee⁴, P Timmerman², and P Williams⁴ ¹Tibotec, Mechelen, Belgium; ²Johnson&Johnson PRD, Beerse, Belgium; ³Johnson&Johnson PRD, Val-de-Reuil, France; and ⁴Johnson&Johnson PRD, High Wycombe, UK
557	Novel 8-Substituted Dipyridodiazepinone Inhibitors with Broad-spectrum of Activity against NNRTI-resistant HIV-1 Christiane Yoakim*, P Bonneau, R Déziel, L Doyon, J Duan, I Guse, S Landry, É Malenfant, J Naud, W Ogilvie, J O'Meara, B Thavonekham, B Simoneau, M Bös, and M Cordingley Boehringer Ingleheim Ltd R&D, Laval, Canada
558	Antiviral Characterization and Human Experience with BILR 355 BS, a Novel Next-generation Non-Nucleoside Reverse Transcriptase Inhibitor with a Broad Anti HIV-1 Profile Pierre Bonneau*¹, P Robinson², J Duan¹, L Doyon¹, B Simoneau¹, C Yoakim¹, M Garneau¹, M Bos¹, M Cordingley¹, B Brenner³, B Spira³, M Wainberg³, F Huang², K Drda², C Ballow⁴, and D Mayers² ¹Boehringer Ingleheim Ltd R&D, Laval, Canada; ²Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA; ³McGill Univ AIDS Ctr, Jewish Gen Hosp, Montreal, Canada; and ⁴Buffalo Clin Res Ctr, NY, USA
559	HIV-1 Acquires Resistance to New NNRTI, Thiazol Derivatives, through Steric Hindrance with Multiple Mutations Eiichi Kodama*¹, N Masuda², M Orita³, O Yamamoto³, M Fujii³, S Kageyama³, M Ohta³, T Hatta³, H Inoue³, H Suzuki³, K Sudo³, Y Shimizu³, and M Matsuoka¹ ¹Inst for Virus Res, Kyoto Univ, Japan; ²Yamanouchi Pharma Co, Ltd Tsukuba, Japan; and ³Yamanouchi Pharma Co, Ltd Tsukuba, Japan
560	24-Week RESIST Study Analyses: the Efficacy of Tipranavir/Ritonavir Is Superior to Lopinavir/Ritonavir, and the TPV/r Treatment Response is Enhanced by Inclusion of Genotypically Active Antiretrovirals in the Optimized Background Regimen D Cooper*¹, C Hicks², P Cahn³, A Lazzarin⁴, S Walmsley⁵, K Arasteh⁶, C Katlama⁷, B Grinsztejn⁸, S Moreno⁹, N Clumeck¹⁰, P Lopez¹¹, G Mukwaya¹², J Villacian¹², V Kohlbrenner¹², and S McCallister¹² ¹St Vincent's Hosp, Univ of New South Wales, Sydney, Australia; ²Duke Univ Med Ctr, Durham, NC, USA; ³Fndn Huésped, Buenos Aires, Argentina; ⁴Fndn Centro San Raffaele del Monte Tabor, Milan, Italy; ⁵Toronto Gen Hosp, Canada; ⁶Epimed GmbH, c/o Vivantes Auguste-Viktoria Hosp, Berlin, Germany; ⁷Hosp Pitie-Salpetriere, Paris, France; ⁸Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil; ⁹Hosp Ramon y Cajal, Madrid, Spain; ¹⁰Ctr Hosp Univ, Univ Med Ctr, Brussels, Belgium; ¹¹Ctr Guadalajara, Mexico City, Mexico; and ¹²Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA
561	in vitro Selection and Characterization of HIV with Reduced Sensitivity to AG-001859 Jennifer Hammond*, L Jackson, J Graham, W Blair, and A Patick Pfizer Global Res and Devt, La Jolla, CA, USA
562	UIC-02031: A Novel Nonpeptidic Protease Inhibbitor Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant HIV-1 in vitro Yasuhiro Koh*¹, H Nakata¹, H Ogata-Aoki¹, S Leschenko², A Ghosh², and H Mitsuya^1,3 ¹Kumamoto Univ Sch of Med, Japan; ²Univ of Illinois at Chicago, USA; and ³NCI, NIH, DHHS, Bethesda, MD, USA
563	640385, a Novel HIV-1 Protease Inhibitor: Safety and Pharmacokinetics following Repeat Administration with and without Ritonavir in Healthy Subjects Susan Ford*, S Reddy, M Anderson, S Murray, J Ng-Cashin, and M Johnson GlaxoSmithKline, Research Triangle Park, NC, USA